Indraprastha Medical Corporation Limited (INDRAMEDCO:NSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Indraprastha Medical Corporation Limited stock forecast from 0 analysts, the average analyst target price for Indraprastha Medical Corporation Limited is not available over the next 12 months. Indraprastha Medical Corporation Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Indraprastha Medical Corporation Limited is Bullish , which is based on 13 positive signals and 5 negative signals. At the last closing, Indraprastha Medical Corporation Limited’s stock price was INR 267.70. Indraprastha Medical Corporation Limited’s stock price has changed by +15.84% over the past week, +51.80% over the past month and +210.38% over the last year.
No recent analyst target price found for Indraprastha Medical Corporation Limited
No recent average analyst rating found for Indraprastha Medical Corporation Limited
Company Overview Indraprastha Medical Corporation Limited
Indraprastha Medical Corporation Limited provides hospital services in India. It offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, endovascular surgery, endocrinology, ENT, fetal medicine, laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, ophthalmology, pediatric sciences, urology, and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neurology/neurosurgery, orthopedics, robotic surgery, and transplant, as well as laboratory services, internal medicine, preventive health, sleep medicine and clinical care, and transfusion medicine. The company was founded in 1983 and is based in New Delhi, India. Read Less
Indraprastha Medical Corporation Limited provides hospital services in India. It offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietet...Read More
Frequently Asked Questions About Indraprastha Medical Corporation Limited (INDRAMEDCO:NSE) Stock
Stock Target Advisor's fundamental analysis for Indraprastha Medical Corporation Limited's stock is Bullish .
INDRAMEDCO:NSE stock's dividend yield is 1.84%.
Our analysis grades INDRAMEDCO:NSE stock's dividend yield at B+. This means that INDRAMEDCO:NSE stock's dividend yield is above 89% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this INDRAMEDCO:NSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on INDRAMEDCO:NSE's stock to indicate what its average analyst target is.
INDRAMEDCO:NSE stock's Price/Earning ratio is 13.94.
Our analysis grades INDRAMEDCO:NSE stock's Price / Earning ratio at A+. This means that INDRAMEDCO:NSE stock's Price/Earning ratio is above 0% of the stocks in the Medical Care Facilities sector in the NSE exchange.
Based on this INDRAMEDCO:NSE may be undervalued for its sector.
The last closing price of INDRAMEDCO:NSE's stock was INR 267.70.
The most recent market capitalization for INDRAMEDCO:NSE is INR 15.79B.
Unfortunately we do not have enough analyst data on INDRAMEDCO:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Indraprastha Medical Corporation Limited's stock.
As per our most recent records Indraprastha Medical Corporation Limited has 2,947 Employees.
Indraprastha Medical Corporation Limited's registered address is Sarita Vihar, New Delhi, India, 110076.
You can get more information about it from Indraprastha Medical Corporation Limited's website at https://www.delhi.apollohospitals.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for INDRAMEDCO:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
